Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors Metastatic to the Liver 1Melanoma 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Rose Bengal B × Clear all
NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Provectus Pharmaceuticals

Phase 1/2 Unknown
50 enrolled
Dermatologic

Melanoma

NCT02693067 2023-02-08

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
12 enrolled
EndocrineNET

Neuroendocrine Tumors Metastatic to the Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡